Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.  In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Therapeutics to Present at Two Investor Conferences


CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis


CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology

Upcoming Event

Sep 26 2017 9:45 am ET

Cantor Fitzgerald Global Healthcare Conference

September 26, 2017 at 9:45 am ET

InterContinental New York Barclay Hotel

Q2 2017 Quarterly Results